REG - Oxford BioDynamics - Result of AGM

Oxford BiodynamicsAnnouncement

26/01/2026 12:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260126:nRSZ3856Qa&default-theme=true

RNS Number : 3856Q  Oxford BioDynamics PLC  26 January 2026

 

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Result of AGM

Oxford, UK - 26 January 2026 - Oxford BioDynamics Plc (AIM: OBD, the
Company), a precision clinical diagnostics company bringing specific and
sensitive tests to the practice of medicine based on its EpiSwitch® 3D
genomics platform, announces that all resolutions proposed at the Company's
Annual General Meeting, held earlier today, were duly passed. The proxy votes
received for the AGM were as shown below:

 Resolution                                                                      Votes for      %      Votes against  %      Chairman's Discretion  %     Abstentions / Votes withheld
 Ordinary Resolutions
 1.   To receive the financial statements and the reports of the Directors       1,913,765,673  99.96  13,252         0.00   722,754                0.04  687,222
 and the Auditors for the year ended 30 September 2025
 2.   To approve the report of the Remuneration Committee for the year ended     1,200,415,738  62.71  713,218,083    37.26  722,754                0.04  832,326
 30 September 2025
 3.   To elect Peter Presland as a Director of the Company                       1,910,939,324  99.82  2,808,322      0.15   722,754                0.04  718,501
 4.   To re-elect Dr Alexandre Akoulitchev as a Director of the Company          1,910,863,980  99.81  2,881,251      0.15   722,754                0.04  720,916
 5.   To re-elect Dr David Holbrook as a Director of the Company                 1,199,722,309  62.67  714,042,922    37.30  722,754                0.04  700,916
 6.   To re-elect Iain Ross as a Director of the Company                         1,907,689,355  99.64  6,075,280      0.32   722,754                0.04  701,512
 7.   To re-elect Paul Stockdale as a Director of the Company                    1,910,898,407  99.81  2,866,824      0.15   722,754                0.04  700,916
 8.   To re-appoint Grant Thornton UK LLP as Auditors of the Company             1,913,079,280  99.93  676,192        0.04   722,754                0.04  710,675
 9.   To authorise the Directors to set the remuneration of the Auditor          1,911,916,081  99.87  1,827,754      0.10   722,754                0.04  722,312
 10. To authorise the Directors to allot shares in the Company                   1,910,460,099  99.80  3,113,162      0.16   722,754                0.04  892,886
 Special Resolutions
 11. To disapply statutory pre-emption rights in connection with a rights issue  1,845,833,984  96.42  67,888,556     3.55   722,754                0.04  743,607
 or other pre-emptive issue
 12. To disapply statutory pre-emption rights in connection with an acquisition  1,846,582,870  96.46  67,136,765     3.51   722,754                0.04  746,512
 or a specified capital investment
 13. To authorise the Company to make market purchases of its own shares         1,852,677,167  96.77  61,083,956     3.19   722,754                0.04  705,024

 

The Board notes the proportion of shareholders' votes which were against
ordinary resolutions two and five.  The Board intends to consult with
shareholders to understand their views.

-Ends-

For further details please contact:

  Oxford BioDynamics Plc                       Tel: +44 (0)1865 518910
 Iain Ross Executive Chairman

 Paul Stockdale, CFO
 Shore Capital - Nominated Adviser and Broker  Tel: +44 (0)20 7408 4090
 Stephane Auton / Lucy Bowden
 OAK Securities - Joint Broker                 Tel: +44 (0)20 3973 3678
 Matthew Clarke / Tim Dainton / Calvin Man
 Camarco - Financial PR                        Tel: +44 (0)20 3757 4980
 Marc Cohen / Tilly Butcher / Fergus Young     OBDFinancial@camarco.co.uk

 

 

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6Njo3YmRiOmUxODM2ZWZhYmIxNjdhMjFiNTMxOThjNjE0YzMwYzg5YzA1MjI2MmYxMGY0ZTU1MzdjYzdlYzg1NDA5ZTcyOWU6cDpU)
,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGUNRURNWUAUAR



            Copyright 2019 Regulatory News Service, all rights reserved